PedAM
Pediatric Disease Annotations & Medicines
| Disease | down syndrome |
| Phenotype | C0023470|myeloid leukemia |
| Sentences | 10 |
| PubMedID- 22392565 | Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on children's oncology group trial a2971: a report from the children's oncology group. |
| PubMedID- 25231553 | Prognosis and management of acute myeloid leukemia in patients with down syndrome. |
| PubMedID- 25887863 | Prame immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with down syndrome. |
| PubMedID- 22150305 | myeloid leukemia in down syndrome. |
| PubMedID- 22776818 | Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with down syndrome. |
| PubMedID- 24962331 | Background: most down syndrome children with acute myeloid leukemia (ds-aml) have an overall excellent prognosis, however, patients who suffer an induction failure or relapse, have an extremely poor prognosis. |
| PubMedID- 20113894 | myeloid leukemia in children with down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms. |
| PubMedID- 21557456 | Background: the aim of the jcclsg aml 9805 down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (aml) with down syndrome (ds). |
| PubMedID- 26481183 | Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in down syndrome: a nationwide prospective study in japan. |
| PubMedID- 25587735 | Approximately 20%-30% of tam survivors are at risk of development of acute myeloid leukemia (myeloid leukemia associated with down syndrome, ml-ds). |
Page: 1